We present the most important funding rounds in recent years in the bioinformatics industry, a sector that is growing at an exponential rate. We also analyse the purchase of Intelligent Pharma by Mind The Blue.
Get in touch with our experts.
We present the most important funding rounds in recent years in the bioinformatics industry, a sector that is growing at an exponential rate. We also analyse the purchase of Intelligent Pharma by Mind The Blue.
Mind the ByteAmazon Web Services' technology partner since 2013, offers its technology through a SaaS (Software as a Service) platform and high value-added scientific services.
The Catalan bioinformatics company, chaired by Alfons Nonell-Canals, opened its first European subsidiary in 2015 in the Copenhagen Bio Science Park (Denmark) and in 2016 entered Japan through the Japanese company Filgen, where it expects to have a turnover of €1.2M by 2020.
Its goal for this year is to double its turnover to €600,000 and reach €2M in 2019. In addition, it expects to close a €3M funding round before mid-year.
Intelligent Pharma is a biotechnology company dedicated to the development of computational technologies for drug discovery and the provision of services based on these technologies to pharmaceutical companies, biotechnology companies and research institutes.
The bioinformatics company has an extensive portfolio of exploratory research projects and we participate in research consortia with leading academic groups.
Intelligent Pharma was founded in 2007 at the Barcelona Science Park by Dr. Ignasi Belda (director of the Barcelona Science Park), after detecting the trend of companies outsourcing computational chemistry and the need for a company that could offer customised and specialised services for drug discovery.
The Catalan company has subsidiaries in Munich and Heidelberg (Germany), London (UK) and Alberta (Canada).
Mind The Byte, a Catalan company specialising in computational drug design, has just closed the purchase of Intelligent Pharma, a company in the same sector also located in the Barcelona Science Park (PCB). Although the amount of the transaction has not been disclosed, we know that the payment will be made in cash and through an exchange of shares.
The company chaired by Alfons Nonell-Canals expects to close a €3M financing round before summer to fund the acquisition of Intelligent Pharma and the growth of Mind The Byte. Since 2011, both companies have been able to raise €5.8M of public and private capital.
The acquisition of Intelligent Pharma will allow the Catalan bioinformatics company not only to increase its local and global presence, but also to expand its range of services and accelerate the innovation of its products in the different geographical areas in which it will be present.
According to Nonell-Canals, president of Mind The Byte, "the integration will allow us to complete our portfolio of tools for drug design with the know-how accumulated by Intelligent Pharma after more than 10 years of experience and complementary technologies to those of Mind The Byte, which will be very useful to strengthen our business line".
Bioinformatics is an emerging discipline in which computer science and information technologies are applied to the processing of biological data. It is one of today's fundamental tools for the R&D process in the pharmaceutical industry. "The time needed to develop a drug can be as long as 10 to 15 years and a very long-term investment of hundreds of millions of euros; with these tools we cut costs and time," explains Nonell-Canals.
As stated in the latest report by international consultancy Transparency Market Research (TMR), the global bioinformatics market is experiencing exponential growth, and it is estimated that investment could grow from $2.3 billion in 2012 to $9.1 billion by 2018.
| PROGRAMME | Research and Development Projects (RDP) |
|---|---|
| PUBLIC BODY | CDTI - Ministry of Economy, Industry and Competitiveness. |
| BENEFICIARIES | Individual: Companies National Cooperation: Economic Interest Grouping (EIG) or consortium governed by a private partnership agreement, made up of at least two independent companies and with a maximum of six partners. |
| PURPOSE OF THE PROGRAMME | Research and Development projects are business projects of an applied nature for the creation and significant improvement of a production process, product or service submitted by a single company or a group of companies. Such projects may comprise both industrial research and experimental development activities, as defined in the General Block Exemption Regulation (EC Regulation No 651/2014). |
| CHARACTERISTICS OF THE AID | Projects can be individual or cooperative: A. Individual R&D Projects: - Beneficiaries: companies. - Project duration: the duration of these projects may be from 12 to 36 months. - Project budget: the minimum eligible budget will be €175,000. B. R&D Projects in National Cooperation: - Beneficiaries: the formalisation of an Economic Interest Grouping (EIG) or consortium governed by a private partnership agreement, made up of at least two independent companies and with a maximum of six partners, is required. The creation of balanced consortia, with an adequate size to ensure effective management, will be valued. - Project duration: the duration of these projects may range from 12 to 48 months. - Project budget: the minimum budget to be financed will be of the order of €500,000, with a minimum budget per company of €175,000. The distribution of the participation of each company (or group of related or associated companies) must be balanced, with the participation of a single company not exceeding 65% of the total budget of the project. Eligible expenditure shall be: - Staff costs (researchers, technicians and other auxiliary staff, provided they are exclusively dedicated to the research project). - Costs of instruments and equipment, to the extent and for the period used for the research project, including depreciation where appropriate. - Costs of contractual research, know-how and patents acquired or licensed from external sources at market prices, and the costs of consultancy and equivalent services used exclusively for research activity. - Additional overheads directly arising from the research project. - Other operating expenses, including costs of materials, supplies and similar products, arising directly from the research activity. |
| TYPES OF AID | The financial coverage offered is up to 85% of the approved budget. The aid consists of a repayable tranche and a non-repayable tranche (TNR): (a) The repayable tranche shall be repaid over 10 years with a three-year grace period and the interest rate is equal to one-year Euribor, which shall be fixed at the time the project is approved. If the Euribor is negative, the interest rate is zero. b) The non-repayable tranche is up to 30% of the SME loan amount. The advance payment can be up to 35% of the total budget, with a limit of 250.000 €. |
| DEADLINE | Permanently open. |
| INFORMATION | +34 946 42 41 42 info@abra-invest.com |
M&A in the Pharmaceuticals sector in 2017. Prim acquires Anota for €1.23M.
GPI acquires the 60% from Spain's Hemasoft, specialising in software for blood banks.
Spanish biotech gets backing from investors: 4 companies raised more than €3M in May
Yes you want to look for investors, buying a company or sell your company, contact our experts in Corporate Finance.
EN 
ES